Understanding Molecular Mechanisms of Secondary Resistance in Patients with Metastatic Castrate Resistant Prostate Cancer
Abstract
One of the fundamental ways to slow down the progression of prostate cancer in men is to reduce the action of androgens, suchas testosterone, on prostate cancer tissue. Certain drugs directly reduce androgen levels, while others, such as bicalutamide(Casodex), prevent androgen action on its receptor. However, even with these androgendeprivation therapies, a proportionof cancers escape and progressthis phenomenon is termed primary resistance. To counteract this resistance, a secondgeneration of antiandrogen therapies, namely enzalutamide (Xtandi), apalutamide (Erleada), darolutamide (Nubeqa) andabiraterone (Zytiga) has emerged over the last decade. While each drug effectively overcomes primary resistance, all tumorsfinally escape and progress. Such secondary resistance currently poses a major clinical challenge, as patients rapidly follow adownhill course.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2022
- Accession Number
- AD1168788
Entities
People
- Samir Zaidi
Organizations
- Memorial Sloan Kettering Cancer Center